Minireviews
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. May 16, 2022; 10(14): 4348-4356
Published online May 16, 2022. doi: 10.12998/wjcc.v10.i14.4348
Adipose-derived stem cells in the treatment of hepatobiliary diseases and sepsis
Basri Satilmis, Gizem Selen Cicek, Egemen Cicek, Sami Akbulut, Tevfik Tolga Sahin, Sezai Yilmaz
Basri Satilmis, Tevfik Tolga Sahin, Sezai Yilmaz, Hepatology Research Laboratory, Liver Transplant Institute, Inonu University, Malatya 44000, Battalgazi, Turkey
Basri Satilmis, Department of Biochemistry, Faculty of Pharmacy, Inonu University, Malatya 44000, Battalgazi, Turkey
Gizem Selen Cicek, Department of Anesthesiology and Reanimation, Malatya Training and Research Hospital, Malatya 44000, Yesilyurt, Turkey
Egemen Cicek, Sami Akbulut, Tevfik Tolga Sahin, Sezai Yilmaz, Liver Transplant Institute, Inonu University, Malatya 44000, Battalgazi, Turkey
Author contributions: Satilmis B and Sahin TT designed and wrote the paper; Cicek E and Cicek GS performed the literature analysis; Akbulut AS and Yılmaz S reviewed the paper.
Conflict-of-interest: The authors declare that they have no conflicts of interest for the present study.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tevfik Tolga Sahin, FACS, MD, PhD, Professor, Hepatology Research Laboratory, Liver Transplant Institute, Inonu University, Battalgazi Malatya, Malatya 44000, Battalgazi, Turkey. tevfiktolgaa@gmail.com
Received: October 11, 2021
Peer-review started: October 11, 2021
First decision: November 15, 2021
Revised: January 13, 2022
Accepted: March 25, 2022
Article in press: March 25, 2022
Published online: May 16, 2022
Processing time: 213 Days and 12.4 Hours
Abstract

Determination of the mesenchymal stem cells is one of the greatest and most exciting achievements that tissue engineering and regenerative medicine have achieved. Adipose-derived mesenchymal stem cells (AD-MSC) are easily isolated and cultured for a long time before losing their stem cell characteristics, which are self-renewal and pluripotency. AD-MSC are mesenchymal stem cells that have pluripotent lineage characteristics. They are easily accessible, and the fraction of stem cells in the adipose tissue lysates is highest among all other sources of mesenchymal stem cells. It is also HLA-DR negative and can be transplanted allogenically without the need for immunosuppression. These advantages have popularized its use in many fields including plastic reconstructive surgery. However, in the field of hepatology and liver transplantation, the progress is slower. AD-MSC have the potential to modulate inflammation, ameliorate ischemia-reperfusion injury, and support liver and biliary tract regeneration. These are very important for the treatment of various hepatobiliary diseases. Furthermore, the anti-inflammatory potential of these cells has paramount importance in the treatment of sepsis. We need alternative therapeutic approaches to treat end-stage liver failure. AD-MSC can provide a means of therapy to bridge to definitive therapeutic alternatives such as liver transplantation. Here we propose to review theoretic applications of AD-MSC in the treatment of hepatobiliary diseases and sepsis.

Keywords: Adipose-derived stem cells; Hepatobiliary diseases; Sepsis; Mesenchymal stem cells; Theoretic application

Core Tip: Adipose-derived mesenchymal stem cells (AD-MSC) are mesenchymal stem cells that have pluripotent lineage characteristics. They are easily accessible, and the fraction of stem cells in the adipose tissue lysates is the highest among all other sources of mesenchymal stem cells. It is also HLA-DR negative and can be transplanted allogenically without the need for immunosuppression. We clearly need alternative therapeutic approaches to treat end-stage liver failure. AD-MSC can provide a means of bridge therapy to definitive therapeutic alternatives such as liver transplantation. We review the theoretic applications of AD-MSC in the treatment of hepatobiliary diseases.